These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 187150)

  • 61. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
    Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
    Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D.
    Wyckoff JH; Osmand AP; Eisenberg RJ; Cohen GH; Rouse BT
    Immunobiology; 1988 May; 177(2):134-48. PubMed ID: 2456985
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cellular interactions in the cytotoxic T lymphocyte response to herpes simplex virus antigens: differential antigen activation requirements for the helper T lymphocyte and cytotoxic T lymphocyte precursors.
    Schmid DS; Rouse BT
    J Immunol; 1983 Jul; 131(1):479-84. PubMed ID: 6223080
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Adjuvant effects of imiquimod on a herpes simplex virus type 2 glycoprotein vaccine in guinea pigs.
    Bernstein DI; Miller RL; Harrison CJ
    J Infect Dis; 1993 Mar; 167(3):731-5. PubMed ID: 8382722
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protective immunization of mice with specific HSV-1 glycoproteins.
    Chan WL
    Immunology; 1983 Jun; 49(2):343-52. PubMed ID: 6303950
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A comparison of T cell responses to glycoprotein B (gB-1) of herpes simplex virus type 1 and its non-glycosylated precursor protein, pgB-1.
    O'Donnell CA; Chan WL
    Clin Exp Immunol; 1991 Oct; 86(1):30-6. PubMed ID: 1655317
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Design of inactivated polyvalent antiherpes vaccines].
    Andonov P; Dundarov S; Bakalov B
    Vopr Virusol; 1979; (6):665-71. PubMed ID: 230648
    [TBL] [Abstract][Full Text] [Related]  

  • 68. DNA immunization confers protective immunity on mice challenged intravaginally with herpes simplex virus type 2.
    Bourne N; Milligan GN; Schleiss MR; Bernstein DI; Stanberry LR
    Vaccine; 1996 Sep; 14(13):1230-4. PubMed ID: 8961510
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of herpes vaccine in a rabbit model following intraocular inoculation of herpes simplex virus.
    Narang HK
    J Infect Dis; 1984 Jun; 149(6):973-9. PubMed ID: 6330241
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cell-mediated immunity against herpes simplex virus envelope, capsid, excreted, and crude antigens.
    Kalimo KO; Joronen IA; Havu VK
    Infect Immun; 1983 Jan; 39(1):24-8. PubMed ID: 6295957
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Protective effects of monoclonal antibodies and immunopurified glycoproteins in primary HSV-1 infection.
    Lukic ML; Liew FY; Chan WL
    Adv Exp Med Biol; 1985; 186():855-61. PubMed ID: 2996318
    [No Abstract]   [Full Text] [Related]  

  • 73. Cell-mediated and humoral immune responses to herpes simplex virus and cytomegalovirus in renal transplant patients.
    Haahr S; Møller-Larsen A; Andersen HK; Spencer ES
    J Clin Microbiol; 1979 Sep; 10(3):267-74. PubMed ID: 226563
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells.
    Ghasemi M; Erturk M; Buruk K; Sonmez M
    Cytotherapy; 2013 Mar; 15(3):352-61. PubMed ID: 23579060
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Preparation and efficacy of an inactivated subunit vaccine (NFUIBHK) against type 2 Herpes simplex virus infection.
    Skinner GR; Williams DR; Buchan A; Whitney J; Harding M; Bodfish K
    Med Microbiol Immunol; 1978 Nov; 166(1-4):119-32. PubMed ID: 214676
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon enhances T cell mediated cytotoxicity of H-2 compatible target cells infected with UV-inactivated herpes simplex virus.
    Sethi KK; Brandis H
    Arch Virol; 1978; 57(2):177-83. PubMed ID: 208490
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Introduction: objectives of herpes simplex virus vaccines seen from a historical perspective.
    Roizman B
    Rev Infect Dis; 1991; 13 Suppl 11():S892-4. PubMed ID: 1664123
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Experimental immunosuppression induced by herpes simplex virus.
    Cappel R; Henry C; Thiry L
    Arch Virol; 1975; 49(1):67-72. PubMed ID: 172950
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.
    Brynestad K; Babbit B; Huang L; Rouse BT
    J Virol; 1990 Feb; 64(2):680-5. PubMed ID: 2153234
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effects of UV irradiation on skin and nonskin-associated herpes simplex virus infections in rats.
    Garssen J; van der Molen R; de Klerk A; Norval M; van Loveren H
    Photochem Photobiol; 2000 Nov; 72(5):645-51. PubMed ID: 11107850
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.